Given previous studies demonstrating that RGS10 is a crucial homeostatic protein in microglia (Butovsky et al., 2014) but its decreased expression in microglia with age as well as in mouse models of neurodegenerative diseases such as MS, AD, and ALS (Kannarkat et al., 2015; Krasemann et al., 2017), it is reasonable to anticipate that increasing RGS10 levels could hold therapeutic potential. This evidence concerns the gene RGS10 and myeloid sarcoma.